Kura Oncology - KURA Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KURA shares.
View KURA analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 1 year price objectives for Kura Oncology's shares. Their KURA share price forecasts range from $25.00 to $40.00. On average, they expect the company's share price to reach $31.20 in the next year. This suggests a possible upside of 159.4% from the stock's current price.
View analysts price targets for KURA or view top-rated stocks among Wall Street analysts.

Kura Oncology's stock was trading at $12.41 at the start of the year. Since then, KURA shares have decreased by 3.1% and is now trading at $12.03.
View the best growth stocks for 2023 here.

Kura Oncology saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 7,090,000 shares, an increase of 5.3% from the February 13th total of 6,730,000 shares. Based on an average daily volume of 821,900 shares, the days-to-cover ratio is currently 8.6 days. Currently, 11.0% of the shares of the stock are sold short.
View Kura Oncology's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our KURA earnings forecast.

Kura Oncology, Inc. (NASDAQ:KURA) released its quarterly earnings data on Thursday, February, 23rd. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.09.

ETFs with the largest weight of Kura Oncology (NASDAQ:KURA) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Kura Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (4.64%), T. Rowe Price Investment Management Inc. (3.99%), Dimensional Fund Advisors LP (2.54%), Artal Group S.A. (2.54%), Victory Capital Management Inc. (2.27%) and Victory Capital Management Inc. (2.27%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Marc Grasso, Thomas James Doyle and Troy Edward Wilson.
View institutional ownership trends.

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KURA stock can currently be purchased for approximately $12.03.

Kura Oncology (NASDAQ:KURA) has a market capitalization of $823.33 million. The company earns $-135,840,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

The company employs 121 workers across the globe.

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for the company is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at ir@kuraoncology.com.